[HTML][HTML] Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …
across multiple cancer types including both solid and hematologic malignancies has …
Differentiation syndrome in acute promyelocytic leukaemia
M Stahl, MS Tallman - British journal of haematology, 2019 - Wiley Online Library
Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients
with APL are treated with all‐trans retinoic acid (ATRA) and/or arsenic trioxide (ATO) …
with APL are treated with all‐trans retinoic acid (ATRA) and/or arsenic trioxide (ATO) …
Functions, therapeutic applications, and synthesis of retinoids and carotenoids
Vitamin A (all-trans-retinol, 1, Figure 1) is considered the most multifunctional vitamin in the
human body. 1 It plays key roles in many physiological processes such as vision …
human body. 1 It plays key roles in many physiological processes such as vision …
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly …
P Fenaux, C Chastang, S Chevret… - Blood, The Journal …, 1999 - ashpublications.org
All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry
S Lehmann, A Ravn, L Carlsson, P Antunovic… - Leukemia, 2011 - nature.com
Our knowledge about acute promyelocytic leukemia (APL) patients is mainly based on data
from clinical trials, whereas population-based information is scarce. We studied APL patients …
from clinical trials, whereas population-based information is scarce. We studied APL patients …
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome …
P Montesinos, JM Bergua, E Vellenga… - Blood, The Journal …, 2009 - ashpublications.org
Differentiation syndrome (DS) can be a life-threatening complication in patients with acute
promyelocytic leukemia (APL) undergoing induction therapy with all-trans retinoic acid …
promyelocytic leukemia (APL) undergoing induction therapy with all-trans retinoic acid …
[HTML][HTML] Acute promyelocytic leukemia (APL): a review of the literature
JJ Jimenez, RS Chale, AC Abad, AV Schally - Oncotarget, 2020 - ncbi.nlm.nih.gov
Abstract Acute Promyelocytic Leukemia (APL) is characterized by a block in differentiation
where leukemic cells are halted at the promyelocyte stage. A characteristic balanced …
where leukemic cells are halted at the promyelocyte stage. A characteristic balanced …
How I treat acute promyelocytic leukemia
MS Tallman, JK Altman - Blood, The Journal of the American …, 2009 - ashpublications.org
Acute promyelocytic leukemia is the first malignant disease highly curable with targeted
therapy directed at a unique molecular abnormality. The characteristic bleeding diathesis is …
therapy directed at a unique molecular abnormality. The characteristic bleeding diathesis is …
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans
retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term results …
retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term results …
The simpler, the better: oral arsenic for acute promyelocytic leukemia
Arsenic trioxide and all-trans retinoic acid have become the frontline treatments for patients
with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a …
with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a …